Background: As atypical polypoid adenomyoma (APA) has been reported to be a hormone-related tumor, we aimed to analyze the efficacy and safety of maintenance hormonal therapy after fertility-preserving treatment of these patients with medroxyprogesterone acetate (MPA). Methods: Data were retrospectively analyzed from patients with APA who were treated with a fertility-preserving regimen including MPA between October 2001 and December 2011. Eighteen patients were treated with MPA and 14 (77.8%) achieved either a complete or a partial response after the planned treatment. Five patients took progestin for maintenance therapy. Results: Eighteen patients were treated for a mean observation period of 96.7 months. While taking the maintenance therapy, no patient had APA relapse. One patient developed welldifferentiated endometrioid adenocarcinoma 18 months after she stopped taking maintenance progestin. Eleven patients without maintenance therapy underwent hysterectomy, andnine of them developed well-differentiated endometrial cancer. Through univariate analysis, there was a significant difference in time to hysterectomy between patients with and without maintenance therapy (P = 0.015). Through multivariate analysis, body mass index (BMI), menstrual status before protocol therapy, maintenance treatment, and pregnancy were found to be significantly associated with a lower risk of hysterectomy. No patient had a recurrence of APA after hysterectomy during the observation period (median, 54 months; range, 2-148 months). Conclusion: No patient showed progression while receiving hormonal therapy, including initial protocol therapy. Maintenance hormonal therapy after treatment with MPA was highly effective and safe, particularly in patients with BMI ≧24 kg/m 2 and irregular menstruation cycle.
Introduction
Atypical polypoid adenomyoma (APA) is a rare uterine neoplasm characterized by proliferation of irregular endometrial glands with squamous metaplasia embedded within a prominent cellular, smooth muscle stroma. It has an architecturally complex and cytologically atypical glandular component that can be confused with well-differentiated adenocarcinoma. Although APA was previously considered a benign tumor, recent studies have demonstrated its malignant potential and high recurrence rate, leading to malignant transformation (1) (2) (3) (4) (5) (6) (7) . Because it typically occurs in premenopausal women (1) and mainly in women of reproductive age (2), we come across patients who want to preserve their reproductive capacity. Hysteroscopic resection is reported to be a good fertility-preserving treatment option (8) , but the long-term clinical outcome is unclear. Standard clinical management has not been established.
APA is reported to be a hormone-related tumor. Obesity (1), prolonged estrogenic stimulation (9) , and infertility (10, 11) are among the causes of the disease. Although APA has been mainly treated surgically, it may not be a rational treatment option. We believe that treatment with progestin may be a good option, since it is used for endometrial cancer and atypical endometrial hyperplasia. We have previously reported the efficacy of treatment of these patients with medroxyprogesterone acetate (MPA) (12, 13) . Although a high response rate (77.8%) was obtained with MPA, the recurrence rate was also high.
We hypothesized that continuous hormonal therapy can reduce the recurrence rate of APA. As maintenance treatment with progestin was associated with a higher rate of long-term success for the treatment of endometrial cancer (14) , we retrospectively analyzed data from patients with APA who were treated with maintenance therapy. This is the first report on maintenance therapy for preventing the recurrence of APA.
Patients and methods
After approval by the institutional review board, we searched medical records and found 18 patients with APA who were treated with a fertility-preserving regimen including MPA between October 2001 and December 2011. The inclusion criteria of the study were as follows: APA diagnosed by total curettage under general anesthesia; no evidence of metrial invasion on magnetic resonance imaging; if a carcinoma was also present, only patients with Stage IA disease according to the 1988 International Federation of Obstetrics and Gynecology (FIGO) staging system with Grade 1 endometrioid adenocarcinoma were included; age <50 years; no risk factors for thrombosis; and follow-up for more than 1 year after completion of protocol therapy. Among these patients, the risk factors for undergoing hysterectomy were further investigated.
The initial diagnosis in all cases was confirmed by the histological analysis performed by two gynecological pathologists. MPA was administered daily (200-600 mg/day) with low-dose aspirin (100 mg/day) to prevent deep venous thrombosis. Dilatation and curettage biopsy was performed for the initial diagnosis and every 3 months during hormonal therapy. If a patient showed either a complete response or a partial response within 6 months, MPA administration was discontinued. If APA persisted after the sixth month, the treatment was continued for 3 more months. If APA persisted after 9 months of treatment, we recommended hysterectomy or close observation of the course until progression to endometrial cancer was confirmed.
The response to MPA treatment was assessed histologically using specimens obtained from dilatation and curettage or hysteroscopic biopsy. No cases were evaluated by office-based endometrial biopsy. A complete response was defined as the absence of atypical glands, and a partial response was defined as a few atypical glands remaining (less than 5%), without evidence of morule formation or squamous differentiation.
After the protocol treatment, these patients were assessed every 3 months for 2 years by endometrial cytological examination and transvaginal ultrasonography. An endometrial biopsy was performed if atypical endometrial cells were observed or atypical genital bleeding continued. The patients were examined every 4-6 months for another 3 years, and once a year thereafter. The time to recurrence was defined as the period from the date of the final administration of MPA to that of diagnosis of recurrence. After the recurrence had been confirmed by biopsy, we offered the patient a choice between hysterectomy and MPA treatment.
The fertility-preserving period was estimated by Kaplan-Meier analysis. The log-rank test was used to compare the two groups. All comparisons were planned, and the tests were two-sided. A P value < 0.05 was considered to indicate statistical significance. All statistical analyses were performed with R software version 3.0.1.
Compliance with ethical standards
The study was approved by the institutional review board of the Cancer Institute Hospital and was conducted in accordance with the 1964 Helsinki Declaration. All patients gave their informed consent prior to their inclusion in the study.
Results

Patient characteristics
Eighteen patients were treated between October and December 2011. Their characteristics are shown in Table 1 . The mean age was 33.6 years (range, 26-45 years), the menstrual cycle was irregular in seven patients, the mean body mass index (BMI) was 21.9 kg/m 2 , all patients were nulliparous, and seven patients were not married at the time of diagnosis.
Treatment outcomes
The mean observation period was 96.7 months (median, 94 months; range, 22-179 months). Fourteen patients (77.8%) achieved either a complete or a partial response after the planned treatment. Although we recommended hysterectomy for the four patients with persistent APA, no patient underwent hysterectomy at that time. Among the 14 patients who achieved either a complete or a partial response after the planned treatment, five patients took progestin for maintenance therapy; none of these five patients were married.
The details of maintenance therapy of the five patients are listed in Table 2 . Patient 1 was married during the course of maintenance therapy and conceived a baby after 25 months of Holmstrom therapy; she is now lactating. Patient 2 is not married and is now taking oral contraceptives. Patient 3 was married during the course of maintenance therapy and conceived a baby. She restarted maintenance therapy after lactation. This patient's detailed clinical course has been previously reported (13) . Patient 4 had a recurrence of APA 13 months after the first protocol, and additional MPA (400 mg/day for 6 months) was administered. After achieving a complete response with additional MPA, she started taking dienogest, which she planned to continue for 37 months until she was 43 years old. However, well-differentiated endometrioid adenocarcinoma was diagnosed 18 months after she stopped taking dienogest. Total laparoscopic HR and salpingooophorectomy were performed. Patient 5 was married after completing protocol therapy. During the observation period, she took oral contraceptives for 7 months for algomenorrhea. After she stopped taking oral contraceptives, APA did not recur. Twelve patients eventually underwent hysterectomy. The mean time to hysterectomy was 44.7 months (median, 39 months; range, 19-84 months). Ten of them were diagnosed with well-differentiated endometrioid adenocarcinoma. None of these patients had a recurrence of APA after hysterectomy during the observation period (median, 54 months; range, 2-148 months).
Maintenance treatment was significantly associated with a lower risk of hysterectomy (P = 0.008) (Fig. 1) . Statistical analysis was performed to find significant factors predicting hysterectomy after protocol therapy. On univariate analysis, maintenance treatment was the only significant factor associated with a lower risk of HR (0.098; 95% CI, 0.012-0.78; P = 0.015). On multivariate analysis, BMI, menstruation status, maintenance treatment and pregnancy were also significantly associated with a lower risk of HR (Table 3) .
Discussion
In this study, we made two important clinical findings. First, maintenance hormonal therapy in patients with APA after treatment with MPA significantly improved recurrence-free survival. The fertilitypreserving period, i.e. hysterectomy-free survival, was significantly different between patients receiving and not receiving hormonal therapy. Second, maintenance treatment with progestin followed by MPA is a safe treatment for APA.
So far, APA has mainly been treated surgically (8) . In our experience, however, surgical resection can result in early recurrence. Since APA was considered a hormone-related tumor (15) , hormonal therapy was suggested as a potential treatment option. Although we reported a high sensitivity (77.8%) of MPA for APA, the recurrence rate was high (12) . Therefore, we focused on maintenance hormonal therapy. This strategy was supported by the results of hormonal treatment of early endometrial cancer. Park et al. reported that maintenance therapy with oral progestin improved recurrence-free survival (14) . Because APA is thought to be a precancerous lesion of endometrial cancer, hormonal therapy for APA, which has similar characteristics to those of endometrial cancer, might be effective. Endometrial cancer in younger women was frequently associated with exposure to an excessive unopposed estrogen environment or a predisposing condition such as polycystic ovary syndrome, chronic anovulation or obesity (16, 17) . Hormonal treatment to create an appropriate environment is, therefore, a reasonable way to treat these diseases. In our study, no patient had disease progression while receiving maintenance therapy, including initial protocol therapy.
BMI and pregnancy were proven to be risk factors for endometrial cancer in previous studies (14, 16, 17) . In our study, similar results were obtained. The BMI of Japanese women with APA and atypical hyperplasia of the endometrium is lower than that of patients in other countries. Matsumoto (18) .
These data imply that factors other than obesity are the main causes of APA in Japanese women. Hence, we used the lower cut-off value of 24 kg/m 2 . Wong et al. reported recurrence of APA after pregnancy (11) . Although they thought that high estrogen levels during pregnancy do not induce APA and high progesterone levels during pregnancy may play a protective role, recurrence of APA was diagnosed soon after pregnancy. Hormonal status during pregnancy may not suppress APA for a long time after delivery.
Although 12 patients underwent hysterectomy, the oncologic outcomes of these patients were excellent. Because APA is a precancerous lesion of the endometrium, 12 of 18 patients (66.7%) underwent hysterectomy during the long-term observation period. No patient had a recurrence after hysterectomy.
The limitations of our study include its retrospective nature and the small sample size (because of the rarity of the disease). Moreover, because the maintenance hormonal therapy was different among the five patients, we cannot tell which progestin to recommend. However, similar to the study of Park (14), it is not the type of progestin that is important but the administration of it. We have shown that maintenance hormonal therapy after MPA treatment results in a long fertility-preserving period. Furthermore, no patient had disease progression during hormonal therapy, including initial protocol therapy. Close observation of patients with APA is needed because of its high recurrence rate after hormonal therapy. However, in our study, no patient had a recurrence after hysterectomy. With an excellent oncologic outcome, hormonal treatment may be a safe and effective. 
